Evidence map›Paper›PMID 37304264›Full record

ArticleFrontiers in immunology2023

Anti-staphylococcus aureus adaptive immunity is impaired in end-stage renal disease patients on hemodialysis: one-year longitudinal study.

Anne Darbouret-Hervier, Nada Assi, Marie-Jeanne Asensio, Beatrice Bernabe, Aurélie Lechevallier, Raffaella Iantomasi, Bachra Rokbi, Elisabeth Botelho-Nevers, Sophie Ruiz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Anne Darbouret-HervierResearch Department, Sanofi, Marcy l'Etoile, France.
Nada AssiResearch Department, Sanofi, Marcy l'Etoile, France.
Marie-Jeanne AsensioResearch Department, Sanofi, Marcy l'Etoile, France.
Beatrice BernabeResearch Department, Sanofi, Marcy l'Etoile, France.
Aurélie LechevallierResearch Department, Sanofi, Marcy l'Etoile, France.
Raffaella IantomasiResearch Department, Sanofi, Marcy l'Etoile, France.
Bachra RokbiResearch Department, Sanofi, Marcy l'Etoile, France.
Elisabeth Botelho-NeversInfectious Diseases Department, University Hospital, Saint-Etienne, France.
Sophie RuizResearch Department, Sanofi, Marcy l'Etoile, France.
Sanofi (France) · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patients with end-stage renal disease (ESRD) display defects in adaptive and innate immunity, increasing susceptibility to infection. Methods: A longitudinal prospective study was carried out at two medical centers and included 48 ESRD patients who started chronic hemodialysis (HD) treatment ≤3 months before inclusion. Control samples were taken from 62 consenting healthy blood donors. Blood samples were obtained from ESRD patients at each visit, on month (M) 0 (beginning of HD), M6 and M12. Around 50 immunological markers of adaptive and innate immunity were assessed to compare immune responses to Results: Conclusion: All together, these results show that adaptive immunity was largely impaired in ESRD patients, whereas innate immunity was less impacted and tended to be restored by HD.

Indexed as

Kidney Failure, ChronicStaphylococcus aureusAdaptive ImmunityHumansImmunoglobulin GIronLongitudinal StudiesProspective StudiesRenal DialysisImmunoglobulin GIronB-LymphopeniaESRDhemodialysisimmune dysregulationlongitudinal studyStaphylococcus aureus

Identifiers

PMID37304264
PMCPMC10250961
OpenAlexW4378473343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.